Drug intelligence / Profile preview

SPARC-147709

Development stage: Phase 1
Lead developer: Sun Pharmaceutical Industries
Modality: Small Molecules
Administration: Oral

Overview

SPARC-147709 is a small molecule drug candidate developed by Sun Pharmaceutical Industries. It is being investigated primarily for the treatment of neoplasms, including multiple myeloma, and potentially for immune system-related conditions. The compound is designed as a highly lipophilic analogue to promote lymphatic drug transport and enhance the release of its parent therapeutic agent. Its mechanism of action and specific molecular targets have not been publicly disclosed. As of now, its highest reported development status is pending or in early clinical evaluation (Phase 1), with ongoing studies such as bioequivalence trials in patients with multiple myeloma[1][2][3][4].

Other names: Liposomal doxorubicin SPARC

Targets

TOP2A (DNA topoisomerase II)DNA

Beyond the preview

Go deeper on SPARC-147709.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPARC-147709.

Explore the full profile